Otolaryngology Doctors in Wheeling, WV Accepting Medicare

4 Otolaryngology doctors found. Showing 1 - 4

Dr. Raymond A Hinerman, DDS, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 30 Medical Park Ste 223, Wheeling, WV 26003 Phone: 304-234-2060    Fax: 304-234-2070

Jeremy J Tiu, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 176 Anthoni Ave, Wheeling, WV 26003 Phone: 304-234-2060    Fax: 304-234-2070

Larry A Dodd, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 20 Medical Park, Suite 223, Wheeling, WV 26003 Phone: 304-234-2061    Fax: 304-234-2070

Christopher Tiu, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 176 Anthoni Ave, Wheeling, WV 26003 Phone: 304-234-2060    Fax: 304-234-2070

News Archive

Identifying druggable targets on an essential SARS-CoV-2 protein

In a research paper recently uploaded to the preprint server bioRxiv by Newman et al. (March 15th, 2021) the structure and role of one such protein: NSP13, is investigated, with two appealingly druggable targets being identified, possibly opening a new route towards a novel SARS-CoV-2 antiviral agent.

Hospital dramatically increases transplant donations by integrating bereavement and donor services

A UK hospital that combined its bereavement and donation services saw a forty-fold increase in tissue donations, such as corneas, in just five years, according to research in the August issue of Anaesthesia.

Researchers study the experiences of veterans who have suffered spinal cord injuries

People who live with spinal injuries often say that the first year of recovery is the toughest-not only for them, but their caregivers as well.

Study details exactly how Her2 gene promotes progression and spread of breast cancer cells

Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells.

Lux Biosciences receives CRL for Voclosporin

Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding their New Drug Application (NDA) for voclosporin. Lux's NDA, filed in February 2010, seeks approval for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye.

Read more Medical News

› Verified 9 days ago